BioCentury | Jun 24, 2020
Finance

AsclepiX aims for basket of retinal indications with $35M series A

...his firm’s thesis, but he initially agreed to become an independent director, then its chair. Perceptive Xontogeny Venture Fund...
BioCentury | Apr 1, 2020
Finance

March 31 Quick Takes: Cowen leads €47M addition to AM-Pharma's C round; plus Zucara, CellFe, Zentalis and Shanghai Junshi

...round Zucara Therapeutics Inc. raised $21 million in a series A round led by the Perceptive Xontogeny Venture Fund...
BioCentury | Dec 10, 2019
Finance

Perceptive launches $210M early-stage fund tied to Garabedian’s accelerator Xontogeny

...fund that will invest in companies the accelerator is nurturing through the clinical proof-of-concept stage. Perceptive Xontogeny Venture Fund...
BioCentury | Aug 14, 2019
Financial News

$60M B round to propel Landos through Phase II IBD trials

...M&A, said Bassaganya-Riera. New investor RTW Investments and series A investor Perceptive Advisors, via the Perceptive Xontogeny Venture Fund...
...Osage University Partners and PBM Capital. Undisclosed other investors also participated. It's the first time Perceptive Xontogeny Venture Fund...
Items per page:
1 - 4 of 4
BioCentury | Jun 24, 2020
Finance

AsclepiX aims for basket of retinal indications with $35M series A

...his firm’s thesis, but he initially agreed to become an independent director, then its chair. Perceptive Xontogeny Venture Fund...
BioCentury | Apr 1, 2020
Finance

March 31 Quick Takes: Cowen leads €47M addition to AM-Pharma's C round; plus Zucara, CellFe, Zentalis and Shanghai Junshi

...round Zucara Therapeutics Inc. raised $21 million in a series A round led by the Perceptive Xontogeny Venture Fund...
BioCentury | Dec 10, 2019
Finance

Perceptive launches $210M early-stage fund tied to Garabedian’s accelerator Xontogeny

...fund that will invest in companies the accelerator is nurturing through the clinical proof-of-concept stage. Perceptive Xontogeny Venture Fund...
BioCentury | Aug 14, 2019
Financial News

$60M B round to propel Landos through Phase II IBD trials

...M&A, said Bassaganya-Riera. New investor RTW Investments and series A investor Perceptive Advisors, via the Perceptive Xontogeny Venture Fund...
...Osage University Partners and PBM Capital. Undisclosed other investors also participated. It's the first time Perceptive Xontogeny Venture Fund...
Items per page:
1 - 4 of 4